Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

Patients with non-metastatic GIST treated with neoadjuvant TKIs prior to surgery experienced a benefit which led to less ...

Rare cancers are less known and pose challenges due to limited research and diagnostic difficulties. Environmental factors, ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

A live webcast can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay will be available approximately two hours after the completion of ...

6 The Carney triad, caused by mutation of the SDH gene, is a rare, nonhereditary condition characterized by the presence of 3 different types of tumors: GISTs ... chronic pain, gastrointestinal ...

GSK has announced that it will be expanding its gastrointestinal (GI) cancer pipeline by acquiring IDRx in a deal ... being developed as a first- and second-line therapy for gastrointestinal stromal ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...